It’s ironic that the rigid nature of clinical research depends on a largely fragile variable: people. Even the most promising therapy cannot succeed in development if the study evaluating it struggles to keep participants engaged. Recruiting patients is already a...

Amgen’s subcutaneous reformulation of Tepezza meets its Phase 3 primary endpoint in thyroid eye disease, Lipocine’s oral brexanolone suffers a significant Phase 3 setback in postpartum depression, and NervGen Pharma secures FDA alignment on the RESTORE Phase 3...

The Growing Strain on Clinical Trial Operations Clinical trials have become increasingly diverse, complex, and expensive over the past decade. As the industry moves toward a more globalized model, managing timelines, coordinating across clinical functions, and...

Beam Therapeutics' base edited cell therapy for sickle cell disease earns a landmark NEJM publication, Immunovant's batoclimab misses in two Phase 3 thyroid eye disease trials, Seaport Therapeutics unlocks a novel anxiety treatment pathway, and Eli Lilly's oral GLP-1...

We work with hospitals, clinics, and health systems across the country every day. Over the past few years, one thing has become very clear: filling a specialist role is harder than it used to be, it takes longer, and the consequences of getting it wrong reach further...

Drug development is one of the most expensive and time-intensive innovation processes in the world. Estimates from the Tufts Center for the Study of Drug Development suggest that bringing a new drug to market can cost over $2.6 billion and take more than a decade of...

Medication non-adherence and dropout have long been labeled “known problems” in the clinical trial space. Yet despite years of tinkering with the formula, these challenges have only become “well-known problems.” Operational efficiencies and innovation, digital...